Robert Kraft Sells 3,858 Shares of Medpace (NASDAQ:MEDP) Stock

Key Points

• Director Robert Kraft sold 3,858 Medpace shares at an average price of $617.81, generating approximately $2.38 million. His remaining ownership fell 80.16% to 955 shares.
• Medpace reported strong quarterly results, with EPS of $4.25 beating estimates of $3.98 and revenue rising 17.2% year over year to $707.33 million.
• The stock recently traded at $600.65, while analysts maintained a consensus “Hold” rating and an average price target of $584.18; institutional investors own nearly 78% of shares.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) Director Robert Kraft sold 3,858 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the sale, the director owned 955 shares of the company's stock, valued at $590,008.55. This represents a 80.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Medpace Stock Performance

Medpace stock traded down $10.92 during midday trading on Friday, hitting $600.65. 186,741 shares of the company's stock were exchanged, compared to its average volume of 343,212. The firm has a 50-day moving average of $562.52 and a two-hundred day moving average of $493.80. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market cap of $16.76 billion, a PE ratio of 35.21, a P/E/G ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period last year, the company posted $3.10 earnings per share. Medpace's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Trading of Medpace

A number of institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its stake in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Medpace during the second quarter valued at $296,000. Finally, M&T Bank Corp increased its position in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after acquiring an additional 31 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Finally, Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source